Stay updated on ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial
Sign up to get notified when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.

Latest updates to the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedCore content updated to inform users about funding-related operating status and current NIH Clinical Center openness; version updated from v3.1.0 to v3.2.0.SummaryDifference3%

- Check26 days agoChange DetectedPage now shows Revision: v3.1.0 and adds a batch of contact details (phone numbers and emails) for various individuals. Deletion indicates removal of v3.0.2.SummaryDifference0.1%

- Check40 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2; the Back to Top element was removed, with no substantive content changes otherwise.SummaryDifference0.2%

- Check47 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.2%

- Check54 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as new related topics such as Salivary Gland Cancer and various hormones. Notably, previous content related to Oral Cancer and several specific neoplasms has been removed.SummaryDifference4%

- Check69 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%

Stay in the know with updates to ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.